VIP for Cognition: Evidence on Vasoactive Intestinal Peptide
What's breaking down
The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.
Why VIP might help you
- Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.
How these fit together
Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- VIP → immune / autonomic
What the evidence actually shows
This is a count of what is in this ledger — not a claim about all research worldwide.
- Scientific sources catalogued (PubMed, trials, reviews): 4
- Claims tagged human evidence: 1
- Claims tagged preclinical (animal/lab): 3
- Claims tagged anecdotal: 1
- Reddit posts catalogued: 1
- X posts catalogued: 0
- Other anecdote sources (YouTube, Instagram, etc.): 0
- Total sources in chain: 5
Quantified confidence (this ledger): 0.36 / 1.00 — low–moderate — mostly preclinical
Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.
What scientists say
Vasoactive intestinal polypeptide plasma levels associated with affective symptoms and brain structure and function in healthy females (source s1)
Observational human study linking plasma VIP to lower affective symptoms and brain metrics.
Evidence type: Tagged human evidence in this ledger — check sample size and design.
Vasoactive Intestinal Peptide Decreases β-Amyloid Accumulation and Prevents Brain Atrophy in the 5xFAD Mouse Model of Alzheimer's Disease (source s15)
Preclinical study showing amyloid reduction and volume preservation in AD mice.
Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.
VIP Modulation of Hippocampal Synaptic Plasticity: A Role for VIP Receptors as Therapeutic Targets in Cognitive Decline and Mesial Temporal Lobe Epilepsy (source s3)
Review detailing VIP interneuron function in hippocampal learning.
Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.
Select cognitive deficits in Vasoactive Intestinal Peptide deficient mice (source s39)
Demonstrates memory deficits in VIP knockout mice.
Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.
What people say on Reddit
VIP seemed to improve cognitive function but increased depression/irritability — Reddit, r/Peptides (source s24)
Single user anecdote on mixed cognitive and mood effects.
---
Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.
Evidence ledger 5 · tier-ranked · API
Ask this article · 8 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.